Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response
about
Imaging of HCC-Current State of the ArtCombining radiotherapy with sunitinib: lessons (to be) learnedPrognostication and response assessment in liver and pancreatic tumors: The new imagingMetabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentialityRelationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancerQ6, a novel hypoxia-targeted drug, regulates hypoxia-inducible factor signaling via an autophagy-dependent mechanism in hepatocellular carcinomaMultiparametric MR Imaging in Abdominal Malignancies.Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular CarcinomaPractical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretationDCE-MRI of hepatocellular carcinoma: perfusion quantification with Tofts model versus shutter-speed model--initial experience.Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model.Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT.Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRIResponse of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study.Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes.Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic MonotherapyRegional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot studyNovel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients.Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation.Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker.Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead.Data-driven mapping of hypoxia-related tumor heterogeneity using DCE-MRI and OE-MRI.Roles of RUNX in Hypoxia-Induced Responses and Angiogenesis.Contrast agents in dynamic contrast-enhanced magnetic resonance imaging.Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy.Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells.Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma.Dynamic contrast-enhanced MRI of nasopharyngeal carcinoma: a preliminary study of the correlations between quantitative parameters and clinical stage.Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.DCE-MRI-Derived Volume Transfer Constant (Ktrans) and DWI Apparent Diffusion Coefficient as Predictive Markers of Short- and Long-Term Efficacy of Chemoradiotherapy in Patients With Esophageal Cancer.
P2860
Q26768463-C65914D3-F0B0-45F9-AAD8-1DB4AF0AB436Q26800587-F1BCB483-17B1-49B9-BA98-206E93E5FA56Q27021568-F10B7020-3031-427E-89EF-B0F27EE34EF9Q27025007-7A205BA8-7F30-4A1C-B404-60308EED6F96Q28068654-78D489DF-12B4-4D5C-863D-7563697AF2F9Q28301777-4AE1C2D2-2DD2-4DD4-A31E-B1E467DDE788Q30364605-DFA7BB3B-0075-4E61-AD8F-CD9F04F751E1Q30448049-2288DE1A-F56A-42E3-A941-C006528DEE30Q30575110-8A7F253F-A8D2-47E3-8F8D-4967BB7FDB07Q31030824-E24F5BC5-5080-4FA1-9A4D-2874B5B46F16Q31119452-E5D9401F-D72D-4E7B-AA04-7F66E3FE8817Q33688593-D393A2B8-B41C-41E7-AB35-4498704C1DCEQ34089545-8964A831-0110-484A-8CD5-74D770EE081BQ34331739-ADEE57BE-5D91-417E-BF6A-2D7339B0F4A7Q34465123-E0E53BA9-0DB7-45D0-880C-509CAC0BEE51Q35710375-12C2434E-1BC3-4091-B51B-4E27E877D59AQ35772492-2B6C290B-03F9-44EA-9525-E2E621660E09Q35892542-F7CF850A-B79D-4153-90ED-35B0E1F13400Q35929346-0119A34A-01E4-4661-97CA-64E947FDBAE2Q36419100-FFACB6EE-C91A-48D1-9681-0D754F556148Q36641544-66A35A4B-8C30-431B-8CBC-7D968EE52281Q37141152-7D2B473B-0367-4D2E-8B93-5E7ECD949902Q37153834-7FCE76C7-9427-47CB-BFD0-F642F799E9A4Q37660658-79677DA5-7674-4DE1-AED2-757AE855F719Q38036127-7FDDB50C-5A45-4C66-B8FB-877454C7520BQ38600887-75285D52-A41D-4F14-A53F-FA75C4F95D85Q39181432-0DBB20A1-30ED-49EB-A648-2C816488C709Q39246340-4B53A30D-BDA2-435B-B30E-75A86C518A34Q44004251-A62C25CC-A007-4AE2-89F3-858C8B67D079Q47114557-84112E08-29A8-42D2-A4BF-C444D8CF6BF6Q47192935-0648B5D0-7D98-4EFB-9B8B-ADB72C33AAB2Q51155388-965FB0CB-2EF9-48BA-8562-186A269BD7BEQ52149377-9913E787-4072-42CE-A4AA-1FC4FC697E21Q53696357-A1552426-E515-46DD-8A70-7A232FB1C236
P2860
Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Antiangiogenic therapy for pri ...... markers and clinical response
@ast
Antiangiogenic therapy for pri ...... markers and clinical response
@en
type
label
Antiangiogenic therapy for pri ...... markers and clinical response
@ast
Antiangiogenic therapy for pri ...... markers and clinical response
@en
prefLabel
Antiangiogenic therapy for pri ...... markers and clinical response
@ast
Antiangiogenic therapy for pri ...... markers and clinical response
@en
P2093
P2860
P1476
Antiangiogenic therapy for pri ...... markers and clinical response
@en
P2093
Adam C Yopp
Dana Haviland
David H Gultekin
Jinru Shia
Lawrence H Schwartz
Michael I D'Angelica
Mithat Gönen
Nancy Kemeny
Peter J Allen
Ronald P DeMatteo
P2860
P2888
P304
P356
10.1245/S10434-011-1570-1
P577
2011-02-01T00:00:00Z
P5875
P6179
1012237972